Translational Health Sciences, University of Bristol, Bristol, UK.
Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, Bristol, UK.
Arch Orthop Trauma Surg. 2023 Sep;143(9):5927-5934. doi: 10.1007/s00402-023-04803-3. Epub 2023 Feb 17.
Dislocation is a common complication associated with total hip replacement (THR). Dual-mobility constructs (DMC-THR) may be used in high-risk patients and have design features that may reduce the risk of dislocation. We aimed to report overall pooled estimates of all-cause construct survival for elective primary DMC-THR. Secondary outcomes included unadjusted dislocation rate, revision for instability, infection and fracture.
MEDLINE, EMBASE, Web of Science, Cochrane Library and National Joint Registry reports were systematically searched (CRD42020189664). Studies reporting revision (all-cause) survival estimates and confidence intervals by brand and construct including DMC bearings were included. A meta-analysis was performed weighting series by the standard error.
Thirty-seven studies reporting 39 case series were identified; nine (10,494 DMC-THR) were included. Fourteen series (23,020 DMC-THR) from five national registries were included. Pooled case series data for all-cause construct survival was 99.7% (95% CI 99.5-100) at 5 years, 95.7% (95% CI 94.9-96.5) at 10 years, 96.1% (95% CI 91.8-100) at 15 years and 77% (95% CI 74.4-82.0) at 20 years. Pooled joint registry data showed an all-cause construct survivorship of 97.8% (95% CI 97.3-98.4) at 5 years and 96.3% (95% CI 95.6-96.9) at 10 years.
Survivorship of DMC-THR in primary THR is acceptable according to the national revision benchmark published by National Institute for Clinical Excellence (NICE).
脱位是全髋关节置换术(THR)常见的并发症。双动式假体(DMC-THR)可用于高危患者,其设计特点可能降低脱位风险。我们旨在报告择期初次 DMC-THR 所有原因假体总体累积生存率的汇总估计值。次要结局包括未调整的脱位率、因不稳定、感染和骨折而翻修。
系统检索 MEDLINE、EMBASE、Web of Science、Cochrane 图书馆和国家关节登记报告(CRD42020189664)。纳入报告按品牌和假体(包括 DMC 轴承)修正(所有原因)生存率估计值和置信区间的研究。通过标准误差对系列进行加权的荟萃分析。
确定了 37 项报告 39 个病例系列的研究,纳入了 9 项(10494 例 DMC-THR)研究。纳入了来自五个国家登记处的 14 个系列(23020 例 DMC-THR)。所有原因假体总体生存率的汇总病例系列数据为 5 年时 99.7%(95%CI 99.5-100),10 年时 95.7%(95%CI 94.9-96.5),15 年时 96.1%(95%CI 91.8-100),20 年时 77%(95%CI 74.4-82.0)。汇总的关节登记数据显示,5 年时所有原因假体的生存率为 97.8%(95%CI 97.3-98.4),10 年时为 96.3%(95%CI 95.6-96.9)。
根据国家临床卓越研究所(NICE)发布的国家翻修基准,初次 THR 中 DMC-THR 的生存率是可以接受的。